NCT06777264View on ClinicalTrials.gov

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

December 15, 2026

Study Completion Date

January 15, 2027

Conditions

Acute Lymphoblastic LeukemiaB Cell ALL

Interventions

BIOLOGICAL

Biological: single dose of Inaticabtagene autoleucel

Inaticabtagene autoleucel will be transfusioned intravenously at the recommended dose of 0.5×10\^8 (ranging 0.2-0.6×10\^8) viable CAR-T cells.

All Listed Sponsors

lead

First Affiliated Hospital of Zhejiang University

OTHER

NCT06777264 - Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1 | Biotech Hunter | Biotech Hunter